Red Light Therapy for Anxiety & PTSD

Anxiety disorders are the most common mental health conditions worldwide, affecting an estimated 301 million people. PTSD affects roughly 3.9% of the global population at some point in their lives. Standard treatments — SSRIs, SNRIs, benzodiazepines, and cognitive behavioural therapy — help many people, but a significant proportion either do not respond adequately or cannot tolerate the side effects.

Transcranial photobiomodulation (tPBM) — the application of red or near-infrared light to the head to modulate brain function — is an emerging approach that has generated genuine research interest over the past decade. The evidence is early-stage but mechanistically compelling, particularly for anxiety symptoms that overlap with depression and cognitive dysfunction.

How Light Reaches the Brain

The first question most people ask is straightforward: can light actually penetrate the skull and reach brain tissue?

The answer is yes, but with important caveats. Near-infrared light in the 800–850 nm range penetrates bone and tissue more effectively than visible red light. Photon transmission studies have demonstrated that approximately 2–3% of NIR light applied to the forehead reaches the outer cortex at a depth of 20–30 mm. This is sufficient to reach the prefrontal cortex — the brain region most relevant to anxiety, emotional regulation, and executive function.

Red wavelengths (630–670 nm) penetrate less deeply and are largely absorbed by the skin and skull. For transcranial applications targeting brain tissue, NIR wavelengths (810–850 nm) are essential.

The Neuroscience of Anxiety and PBM

Anxiety disorders involve several neurobiological features that photobiomodulation may address:

Prefrontal Cortex Hypoactivity

The prefrontal cortex (PFC) — particularly the right dorsolateral PFC and ventromedial PFC — plays a central role in emotional regulation and threat appraisal. In anxiety disorders, these regions often show reduced metabolic activity, leading to impaired top-down regulation of the amygdala (the brain’s threat detection centre).

Transcranial PBM increases mitochondrial metabolism in the targeted cortical region, effectively boosting the energy available for prefrontal function. This is directly analogous to the mechanism proposed for transcranial direct current stimulation (tDCS) and repetitive transcranial magnetic stimulation (rTMS), both of which have established evidence for anxiety and depression.

Neuroinflammation

Chronic anxiety is associated with elevated neuroinflammatory markers — microglial activation, increased pro-inflammatory cytokines in cerebrospinal fluid, and disrupted blood-brain barrier integrity. PBM has demonstrated anti-neuroinflammatory effects in animal models, reducing microglial activation and lowering TNF-alpha and IL-6 levels in brain tissue.

Mitochondrial Dysfunction

Emerging research links mitochondrial dysfunction to anxiety disorders. The brain consumes approximately 20% of the body’s total energy despite representing only 2% of body mass. When mitochondrial efficiency declines — whether through ageing, chronic stress, or metabolic factors — the energy-intensive processes of emotional regulation and cognitive flexibility are disproportionately affected.

PBM directly targets mitochondrial function via cytochrome c oxidase, potentially restoring the energy balance needed for effective prefrontal cortex function.

Serotonin and Nitric Oxide

PBM increases nitric oxide (NO) availability in irradiated tissue. In the brain, NO functions as a neurotransmitter and neuromodulator involved in serotonergic signalling. The link between NO, serotonin, and anxiety is well-established — SSRIs, the first-line pharmacological treatment for anxiety, work by increasing serotonin availability.

What the Research Shows

Transcranial PBM for Anxiety: Human Studies

Schiffer et al. (2009) published a landmark study in Behavioural and Brain Functions examining transcranial NIR light (810 nm) applied to the forehead in 10 patients with major depression and anxiety. Using a single 4-minute exposure to the right forehead, participants showed significant improvements in both Hamilton Anxiety Rating Scale (HAM-A) and Hamilton Depression Rating Scale (HAM-D) scores at 2 weeks post-treatment. This was a small, open-label study, but it provided the first human evidence for transcranial PBM in mood and anxiety disorders.

Cassano et al. (2015) conducted a case series of transcranial PBM (810 nm, 250 mW/cm²) in patients with major depressive disorder (MDD), many of whom had comorbid anxiety. Treatment was applied to the forehead bilaterally. Significant improvements were observed in both depression and anxiety scores after 6 weeks of treatment (twice weekly sessions). The mean HAM-A score decreased from 14.2 to 8.0, representing a clinically meaningful reduction.

Cassano et al. (2018) followed up with a larger open-label trial examining NIR tPBM (823 nm) in 21 patients with MDD. Anxiety subscale scores improved significantly alongside depression scores. While this study lacked a sham control, the effect sizes were noteworthy: Cohen’s d of 1.05 for anxiety improvement.

Henderson and Morries (2017) published a case series of 39 patients with traumatic brain injury (TBI) treated with transcranial NIR (810 nm and 980 nm). Many patients had comorbid PTSD and anxiety symptoms, and significant improvements were reported in both cognitive function and emotional symptoms, including anxiety.

PTSD-Specific Evidence

Direct evidence for PBM in PTSD is limited but biologically plausible.

Bogdanova et al. (2017) examined transcranial PBM in Gulf War veterans with blast-induced TBI and comorbid PTSD. Using LED arrays delivering 810 nm and 850 nm to multiple cranial sites, the treatment group showed improvements in PTSD symptom scores, sleep quality, and cognitive function over an 8-week treatment course. The study was small (n = 12) but provided the first controlled evidence for tPBM in PTSD.

The rationale for PBM in PTSD extends beyond simple anxiety reduction. PTSD involves:

Prefrontal cortex hypofunction — impaired extinction of fear memories
Amygdala hyperactivation — exaggerated threat response
Hippocampal atrophy — impaired contextual memory processing
Sleep disruption — fragmented sleep architecture

PBM has demonstrated effects on prefrontal metabolism, anti-neuroinflammatory activity (relevant to hippocampal function), and improvements in sleep quality — all relevant to the PTSD symptom profile.

Overlap with Depression Evidence

Much of the anxiety evidence comes from studies primarily targeting depression, where anxiety is measured as a secondary outcome. This is clinically relevant because anxiety and depression commonly co-occur — roughly 60% of people with one condition also have the other.

The most methodologically rigorous PBM depression trial to date — Cassano et al. (2023), a sham-controlled RCT — demonstrated significant improvements in depression scores with transcranial NIR PBM. Anxiety sub-scores also improved, though the study was not powered to detect anxiety-specific effects independently.

Protocol for Anxiety and PTSD

Wavelength

810–850 nm (NIR) — essential for transcranial penetration
Red wavelengths (630–660 nm) do not penetrate the skull adequately for cortical effects

Application Sites

Forehead (bilateral) — targets the dorsolateral and ventromedial prefrontal cortex
Temporal regions — targets temporal cortex and, indirectly, underlying limbic structures
Some protocols include the vertex (top of head) for broader cortical coverage

Dose

Power density: 50–250 mW/cm² at the scalp surface
Energy density: 20–60 J/cm² per site
Treatment time: 10–20 minutes total (divided across application sites)

Frequency

2–3 sessions per week for the initial 6–8 weeks
Most studies showing positive results used a minimum of 12 sessions
Maintenance: 1–2 sessions per week once improvement is established

Duration of Trial

Allow a minimum of 4–6 weeks before assessing response
Some patients in clinical studies did not show significant improvement until week 6–8

Device Options for Transcranial PBM

Transcranial PBM is distinct from general red light therapy — not all devices are suitable.

Purpose-Built Transcranial Devices

Devices such as the Vielight Neuro Gamma and Vielight Neuro Alpha are specifically designed for transcranial PBM. They use 810 nm NIR LEDs positioned at the forehead, temporal regions, and vertex, with intranasal diodes for additional coverage. These devices deliver calibrated doses to the cortex and represent the closest match to clinical research parameters.

Large Panels

A standard red/NIR therapy panel (e.g., Mito Red Light, PlatinumLED) can deliver NIR light to the forehead if used at close range (10–15 cm). This approach is less targeted than purpose-built devices but provides adequate NIR irradiance. Treat the forehead for 10–15 minutes per session with the NIR-only setting.

What Will Not Work

Red-only devices (630–660 nm) — insufficient skull penetration
LED face masks — wrong wavelength range and insufficient power for transcranial effects
Low-power handheld devices — unlikely to deliver adequate energy density to the cortex

Important Caveats

This Is Not a Substitute for Mental Health Treatment

Transcranial PBM for anxiety is an emerging intervention with promising but early-stage evidence. It should not replace:

CBT or other evidence-based psychotherapy — which has decades of robust evidence
Medication — particularly if your anxiety is severe or accompanied by panic attacks, agoraphobia, or suicidal ideation
Crisis intervention — if you are in acute distress, contact your GP, call 111, or attend A&E

Evidence Limitations

Most studies are small (10–40 participants)
Several are open-label (no sham control), which introduces placebo effects
The optimal dose, frequency, and treatment duration have not been established through dose-finding studies
Long-term maintenance protocols are unknown
No studies have directly compared tPBM to established treatments (SSRIs, CBT)

Individual Variation

Response to tPBM appears to vary significantly between individuals. Factors that may influence response include:

Skull thickness (varies considerably between individuals and affects light penetration)
Hair density and colour (dark, thick hair absorbs more light)
Severity and chronicity of the anxiety disorder
Whether the anxiety is primarily cognitive (worry) or somatic (physical symptoms)

Red Light Therapy vs Other Neuromodulation for Anxiety

Approach	Evidence Level	Invasiveness	Cost	Accessibility
CBT	Very strong	Non-invasive	NHS or £50–100/session	Widely available
SSRIs/SNRIs	Very strong	Oral medication	NHS prescription	GP
rTMS	Strong (FDA-cleared for depression)	Non-invasive	£200–400/session	Specialist clinics
tDCS	Moderate	Non-invasive	£100–300 for device	Home devices available
Transcranial PBM	Preliminary	Non-invasive	£300–800 for device	Home devices available
Neurofeedback	Weak-moderate	Non-invasive	£80–150/session	Specialist clinics

The Bottom Line

Transcranial photobiomodulation for anxiety is biologically plausible, supported by a small but consistent body of human evidence, and remarkably safe. The prefrontal cortex activation mechanism aligns with established neuroscience of anxiety disorders, and the overlap with depression evidence is encouraging given the high comorbidity between conditions.

However, the evidence base is not yet strong enough to recommend tPBM as a primary treatment for anxiety or PTSD. It is best positioned as a complementary approach — alongside therapy, medication (if prescribed), and lifestyle interventions.

If you choose to try transcranial PBM, use an 810–850 nm NIR device applied to the forehead, commit to a minimum 6-week trial of 2–3 sessions per week, and maintain whatever existing treatment plan you have in place. Track your symptoms systematically (the GAD-7 is a free, validated self-assessment tool) so you can objectively evaluate whether the intervention is helping.

The field is moving quickly, and larger sham-controlled trials are underway. Within the next few years, we should have considerably clearer answers about the role of light therapy in mental health.

This article is for informational purposes only and does not constitute medical advice. If you are experiencing anxiety or PTSD, please consult a qualified mental health professional. Red light therapy should complement — not replace — established treatments. If you are in crisis, contact the Samaritans (116 123) or your local emergency services.